Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C

Journal of Viral Hepatitis

Volumn 16, Issue 10, 2009, Pages 681-688

  Negro, F ^a,b   Clement S ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cirrhosis; Hepatitis C virus; Interferon ; Metabolic syndrome

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

BODY MASS; BODY WEIGHT; DISEASE COURSE; DRUG DISTRIBUTION; FATTY LIVER; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; OBESITY; TREATMENT OUTCOME;

EID: 70349256049     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01186.x     Document Type: Review

References (85)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009 29 (Suppl. 1 74 81.
2. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009 29 (Suppl. 1 15 18.
3. Bochud PY, Cai T, Overbeck K et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009 (in press).
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
5. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
6. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004 20 : 931 938.
7. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 : 1636 1642.
8. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 29 : 1215 1219.
9. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol 2009 43 : 758 764.
10. Everhart JE, Lok AS, Kim HY et al. Weight related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009 137 : 549 557.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 359.
12. Hanouneh IA, Feldstein AE, Lopez R et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2008 6 : 584 589.
13. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009 51 : 371 379.
14. Cancello R, Tordjman J, Poitou C et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006 55 : 1554 1561.
15. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005 11 : 183 190.
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 1364.
17. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009 29 (Suppl. 2 26 37.
18. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002 8 : 1114 1122.
19. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005 42 : 310 316.
20. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004 114 : 147 152.
21. Thomopoulos KC, Arvaniti V, Tsamantas AC et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006 18 : 233 237.
22. Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002 16 : 185 194.
23. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006 130 : 1661 1669.
24. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001 34 : 428 434.
25. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000 33 : 106 115.
26. Piodi A, Chouteau P, Lerat H, Hézode C, Pawlotsky JM. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology 2008 48 : 16 27.
27. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002 36 : 1266 1272.
28. Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 : 78 85.
29. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001 35 : 307.
30. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125 : 1695 1704.
31. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003 97 : 3036 3043.
32. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007 109 : 2490 2496.
33. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009 44 (Suppl. 19 82 88.
34. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009 2 : 231 237.
35. Muzzi A, Leandro G, Rubbia-Brandt L et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005 42 : 41 46.
36. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005 100 : 1509 1515.
37. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 1008. (Pubitemid 40873917)
38. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008 134 : 416 423.
39. Petta S, Cammà C, Di Marco V et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008 103 : 1136 1144.
40. Cammà C, Petta S, Di Marco V et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology 2009 49 : 195 203.
41. Veldt BJ, Poterucha JJ, Watt KD et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009 9 : 1406 1413.
42. Conover A, Hintz RL, Rosenfeld RG. Direct evidence that the insulin receptor mediates a mitogenic response in cultured human fibroblasts. Horm Metab Res 1989 21 : 59 63.
43. Goldstein RH, Poliks CF, Pilch PF, Smith BD, Fine A. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology 1989 124 : 964 970.
44. Svegliati-Baroni G, Ridolfi F, Di Sario A et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999 29 : 1743 1751.
45. Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001 34 : 738 744.
46. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008 47 : 1856 1862.
47. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008 135 : 111 121.
48. Konishi I, Hiasa Y, Shigematsu S et al. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int 2009 29 : 1194 1201.
49. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003 38 : 639 644.
50. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006 43 : 1177 1186.
51. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001 61 : 2263 2288. (Pubitemid 34081171)
52. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
53. Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000 68 : 556 567.
54. Jacobson IM, Brown RS Jr., Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 46 : 971 981.
55. Sulkowski M, Lawitz E, Shiffman ML et al. Final results of the IDEAL (Individualized Dosing Efficacy versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy) phase IIIb study. J Hepatol 2008 48 (Suppl. 2 S370.
56. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004 27 : 2444 2449.
57. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998 394 : 897 901.
58. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002 123 : 1070 1083.
59. Eguchi Y, Mizuta T, Yasutake T et al. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006 12 : 556 560.
60. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008 52 : 1201 1210.
61. Ziol M, Nhieu JT, Roudot-Thoraval F et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C. J Hepatol 1996 25 : 833 841.
62. Patton H, Patel K, Behling C et al. The impact of steatosis on disease in chronic hepatitis C patients. J Hepatol 2004 40 : 484 490.
63. Fabris P, Floreani A, Carlotto A et al. Impact of liver steatosis on virological response in Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2005 21 : 1173 1178.
64. Akuta N, Suzuki F, Sezaki H et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006 78 : 83 90.
65. Westin J, Lagging M, Dhillon AP et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007 14 : 29 35.
66. Gad RR, Males S, El Makhzangy H et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008 28 : 1112 1119.
67. Rodriguez-Torres M, Govindarajan S, Diago M et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int 2009 29 : 237 241.
68. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 999.
69. Conjeevaram HS, Kleiner DE, Everhart JE et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007 45 : 80 87.
70. Huang JF, Yu ML, Dai CY et al. Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C. Hepatology 2007 46 : 349A.
71. Bortoletto G, Realdon S, Dal Pero F et al. Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C. Hepatology 2007 46 : 361A.
72. Nasta P, Gatti F, Puoti M et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008 22 : 857 861.
73. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 641.
74. Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007 46 : 1009 1015.
75. Poustchi H, Negro F, Hui J et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008 48 : 28 34.
76. Chu CJ, Lee SD, Hung TH et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009 29 : 46 54.
77. Bongiovanni M, Ranieri R, Casana M et al. Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection. J Acquir Immune Defic Syndr 2008 47 : 258 259.
78. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004 165 : 1499 1508.
79. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 55 : 529 535.
80. Gadina M, Hilton D, Johnston JA et al. Signalling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001 13 : 363 373.
81. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004 53 : 413 419.
82. Overbeck K, Genné D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferonalpha and ribavirin. J Hepatol 2008 49 : 295 298.
83. Elgouhari HM, Cesario KB, Lopez R, Zein NN. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts. Hepatology 2008 48 : 383A.
84. Conjeevaram H, Burant CF, McKenna B et al. A randomized, double-blind, placebo-controlled study of PPARgamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 2008 48 : 384A.
85. Romero-Gomez M, Diago M, Andrade RJ et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naïve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial. Hepatology 2008 48 : 380A.